Investigating how MALT1 affects the immune environment in aggressive breast cancer.
Official title: Role of MALT1 in regulating the breast cancer immune microenvironment
Funded at Mayo Clinic Rochester · NIH-11143952 · Data updated 2026-11-12
This study is looking at how a protein called MALT1 affects the immune system and tumor growth in triple-negative breast cancer, especially in African-American and Hispanic women, to find new ways to treat this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | June 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $485,171 |
| NIH project number | 5R01CA273027-03 |
| Project ID | NIH-11143952 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with triple-negative breast cancer, particularly those who are African-American or Hispanic.
✕Less likely to help
Patients with other types of breast cancer or those who do not have triple-negative breast cancer may not benefit from this research.
What this research studies
This research focuses on triple-negative breast cancer (TNBC), which is particularly prevalent among African-American and Hispanic women. The study aims to explore the role of MALT1, a protein involved in cancer signaling, in shaping the immune microenvironment of TNBC. By understanding how MALT1 influences tumor behavior and immune response, the researchers hope to identify new therapeutic targets that could lead to more effective treatments for this challenging cancer type. Patients may be involved in studies that assess the impact of targeting MALT1 on tumor progression and immune response.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve treatment outcomes for patients with triple-negative breast cancer.
How similar studies have gone: Previous research has shown promise in targeting similar signaling pathways in cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Lucas, Peter C — Mayo Clinic Rochester
- Study coordinator: Lucas, Peter C
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.